Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;72(4):e31557.
doi: 10.1002/pbc.31557. Epub 2025 Jan 20.

Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid Tumors

Aaron B Ross  1 , Kriti Puri  2   3 , Thomas L Johnson  1 , Lilliam D Correa  2 , Tami D John  4   5 , Brian Friend  4   5 , Shoba A Navai  1   4 , Nabil Ahmed  1   4   5 , Meenakshi G Hegde  1   4   5 , Bilal Omer  4 , Andras Heczey  4   5 , Baheyeldin M Salem  4   5 , Hossein Tcharmtchi  2 , Rayne H Rouce  4   5 , David H Steffin  4   5 , Robert A Krance  4   5 , Nino C Rainusso  5 , Saleh Bhar  1   2   4   5
Affiliations

Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid Tumors

Aaron B Ross et al. Pediatr Blood Cancer. 2025 Apr.

Abstract

Background: Immune effector cell (IEC) therapies, including chimeric antigen receptor (CAR)-modified T-cell therapy, have shown efficacy in pediatric B-cell acute lymphoblastic leukemia (B-ALL) and are being investigated for other malignancies. A common toxicity associated with IEC therapy is cytokine release syndrome (CRS), which can lead to cardiovascular decompensation due to systemic inflammation. Data are limited regarding cardiovascular adverse effects in children. This study aims to describe the cardiovascular adverse effect profile of IEC therapies in pediatric patients with hematologic and solid tumor malignancies.

Methods: We retrospectively reviewed patients who received IECs directed towards various targets in patients with hematologic, solid, and brain tumor malignancies from January 2014 to June 2023 at Texas Children's Hospital. The primary end point was hypotension requiring vasoactive support and/or heart failure within 30 days of infusion.

Results: A total of 203 patients met inclusion criteria. Pretreatment echocardiogram was available for 142 (70%) pediatric patients, of whom 140 (96%) had normal baseline systolic function. Hypotension requiring vasoactive support occurred in 26 (13%) patients. Hematologic malignancy indications (p = 0.002), total body irradiation (TBI) (p = 0.002), and allogenic hematopoietic stem cell transplants (HCT) (p = 0.035) were associated with increased risk of hypotension requiring vasoactive support. Follow-up echocardiograms were available for 14 patients who met the primary end point, and all showed return to baseline within 6 months.

Conclusions: Significant hemodynamic compromise occurred in a minority of patients treated with IEC therapies. All experiencing cardiac dysfunction had recovery of function, and there was no cardiovascular-related mortality.

Keywords: CAR‐T; cardiology; cardiotoxicity; chimeric antigen receptor; cytokine release syndrome; immunotherapy; oncology.

PubMed Disclaimer

References

    1. H. M. Knochelmann, A. S. Smith, C. J. Dwyer, M. M. Wyatt, S. Mehrotra, and C. M. Paulos, “CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies,” Frontiers in Immunology 9 (2018): 1740.
    1. A. F. Stein‐Merlob, M. V. Rothberg, P. Holman, and E. H. Yang, “Immunotherapy‐Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies,” Current Cardiology Reports 23, no. 3 (2021): 11.
    1. P. D. Lulla, S. Naik, S. Vasileiou, et al., “Clinical Effects of Administering Leukemia‐Specific Donor T Cells to Patients With AML/MDS After Allogeneic Transplant,” Blood 137, no. 19 (2021): 2585–2597.
    1. D. W. Lee, R. Gardner, D. L. Porter, et al., “Current Concepts in the Diagnosis and Management of Cytokine Release Syndrome,” Blood 124, no. 2 (2014): 188–195.
    1. H. Shalabi, V. Sachdev, A. Kulshreshtha, et al., “Impact of Cytokine Release Syndrome on Cardiac Function Following CD19 CAR‐T Cell Therapy in Children and Young Adults With Hematological Malignancies,” Journal for ImmunoTherapy of Cancer 8, no. 2 (2020): e001159.

LinkOut - more resources